Alnylam Archives

News and Trends 25 Jul 2023

Roche and Alnylam to work on RNAi therapeutic to treat hypertension

Roche has announced a partnership with Alnylam to develop and commercialize zilebesiran, an investigational RNAi therapeutic currently in phase 2 for the treatment of hypertension. Hypertension affects more than 1.2…

July 25, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 26 Oct 2022

Partnership between Paradigm4 and Alnylam accelerates drug target discovery

New genetically-validated drug targets are found at accelerated speed using population scale biobank genotype-phenotype datasets after a foundational partnership is formed between Paradigm4 and Alnylam. Paradigm4’s REVEAL integrative analytics platform…

October 26, 2022 - 3 minutesmins - By Liza Laws

In Depth 22 Jul 2022

The coming of age story of RNAi technology

The first RNA interference (RNAi) therapy was approved in 2018, after 20 years in development. What can we expect to see in the RNAi field in the future? After two…

July 22, 2022 - 7 minutesmins - By Farhan Mitha

In Depth 4 Jul 2022

The COVID-19 pandemic has driven RNA therapeutics into the mainstream

As messenger RNA vaccines save lives around the world, and RNA interference drugs are greenlit for rare diseases, the field of RNA therapeutics is now moving faster than ever before.…

July 4, 2022 - 8 minutesmins - By Helen Albert

News and Trends 3 Mar 2020

Alnylam Gets Second RNAi Drug Approval from EMA

US biotech Alnylam Pharmaceuticals has succeeded in getting its second RNAi drug -- for treatment of rare, inherited liver diseases -- approved by the European Medicines Authority just months after…

March 3, 2020 - 2 minutesmins - By Helen Albert

News and Trends 25 Nov 2019

Novartis Enters RNA Therapeutics with Medicines Company Merger

Novartis is to acquire The Medicines Company and its late-stage RNA interference drug designed to protect against cardiovascular disease in twice-yearly shots. Novartis will pay €8.8B ($9.7B) to acquire The…

November 25, 2019 - 3 minutesmins - By Jonathan Smith

alnylam silence therapeutics lawsuit settlement

News and Trends 11 Dec 2018

UK Biotech Settles Lawsuit on the First RNAi Drug

Silence Therapeutics and Alnylam have reached a settlement that puts an end to a legal dispute between them resulting in Silence receiving some royalties on Onpattro, the first RNA interference…

December 11, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

Best in Biotech 18 Dec 2017

Smile! Here are the 12 Biggest Biotech Clinical Successes of 2017

Now that we've got the bad news out of the way, we're here to spread some Christmas cheer with the biggest clinical successes in biotech over the past 12 months.…

December 18, 2017 - 9 minutesmins - By Alex Dale

Infographics 22 Nov 2017

Infographic: What is RNAi Therapy? Targeting the Untargetable

Everything you need to know about what RNAi is, how it works and how it could soon change the way we treat all sorts of diseases. A new wave of…

November 22, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

In Depth 19 Sep 2017

RNA as a Therapy: Reviewing the Future Generation of Therapeutics

You’ve certainly heard about antibodies, peptides and even DNA as therapeutics, but what about RNA? In this review, we paint an overview of what’s up in a young field that…

September 19, 2017 - 9 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 Jul 2017

Sanofi and US Partner Launch Phase III Trial in Hemophilia with RNAi

Alnylam and its partner Sanofi are starting a Phase III program to enter its RNAi drug fitusiran in the competitive hemophilia market. Sanofi and its partner Alnylam have announced the…

July 10, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Nov 2016

RNAi Therapy is Back: Sanofi is firmly on board to treat Hemophilia

Sanofi Genzyme is offering Alnylam up to €93M ($100M) to co-develop and launch a revolutionary RNAi therapy for hemophilia. But is RNAi really such a good investment? Sanofi Genzyme signed a…

November 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

View all companies A-Z

Find new scientific partnerships. Create a free IN-PART account

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inova, the leading platform for biopharma partnering